Method of treating leukemia
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
1. A method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or its N-oxide or a pharmaceutically acceptable salt thereof:
wherein the subject had at least one prior therapy to treat a hematological cancer.
2. The method of claim 1 , wherein the hematological cancer is refractory to the prior therapy.
3. The method of claim 1 , wherein the hematological cancer shows recurrence following remission.
4. The method of claim 1 , wherein the subject received and failed all known effective therapies for the hematological cancer.
5. The method of claim 1 , wherein the hematological cancer is selected from the group consisting of acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, a myeloproliferative disorder, and chronic myelogenous leukemia.
6. The method of claim 1 , wherein the hematological cancer is leukemia.
7. The method of claim 6 , wherein the subject has a leukemia characterized by MLL gene rearrangement.
8. The method of claim 7 , wherein the MLL gene rearrangement is translocation of the MLL gene at 11q23.
9. The method of claim 7 , wherein the MLL gene rearrangement is a partial tandem duplication of the MLL gene.
10. A method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or its N-oxide or a pharmaceutically acceptable salt thereof:
wherein the subject is unable to receive other therapy to treat the cancer due to age or intercurrent illness.
11. The method of claim 1 , wherein the subject is simultaneously being treated with another therapy to treat acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, a myeloproliferative disorder, or chronic myelogenous leukemia.
12. The method of claim 11 , wherein the another therapy is standard of care for the treatment of acute myeloid leukemia.
13. The method of claim 11 , wherein the another therapy is standard of care for the treatment of acute lymphoblastic leukemia.